GILD · Healthcare

GILEAD SCIENCES, INC.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-08

• HIV Prevention PersistenceImportance 23 · Surprise 24
  In the PURPOSE 5 trial, 85.6% of participants receiving twice-yearly injectable lenacapavir remained persistent through Week 52, compared with 46.3% receiving daily oral F/TDF for HIV prevention. The trial included…

News · 2026-11-07

• Acquisition-Related R&D ChargesImportance 52 · Surprise 42
  Gilead recorded about $12 billion in acquired in-process R&D charges tied to deal accounting in a single quarter. The article identifies these charges as the primary reason for the company’s negative…
• Quarterly Dividend DeclarationImportance 13 · Surprise 6
  Gilead pays an annual dividend of $3.28 per share, according to the article. Free cash flow covers the dividend payout about 4.6 times. The article reports trailing-twelve-month EPS of -$3.13 but says the dividend…

News · 2026-11-06

• HIV and PrEP Demand GrowthImportance 59 · Surprise 82
  PURPOSE 5 trial results showed nearly twice the one-year persistence among people starting twice-yearly injectable lenacapavir for HIV prevention compared with people starting daily oral emtricitabine/tenofovir…
• Quarterly Dividend DeclarationImportance 13 · Surprise 6
  Gilead announced a quarterly dividend of $0.82 per share. The digest does not specify the aggregate payout or payment date. The dividend was mentioned alongside the company’s quarterly earnings report.

News · 2026-11-05

• Revenue Performance and MixImportance 41 · Surprise 60
  Gilead reported third-quarter 2026 revenue of US$8.3 billion. The company raised its full-year product sales guidance, but the digest does not give the revised guidance amount or the quarter's year-over-year revenue…
• Guidance and OutlookImportance 41 · Surprise 60
  Gilead raised its full-year product sales guidance in its third-quarter 2026 update. The digest does not specify the revised guidance range or quantify the change. The update also described a larger projected GAAP loss…
• Livdelzi Demand GrowthImportance 34 · Surprise 42
  Phase 3 IDEAL results support expanding Livdelzi (seladelpar) use among people with primary biliary cholangitis (PBC), including patients with lower alkaline phosphatase (ALP) elevation. At week 52, 75.4% of patients…
• Regulatory Approval MilestonesImportance 34 · Surprise 42
  Gilead said it will engage global regulatory authorities based on Phase 3 IDEAL results for Livdelzi (seladelpar) in primary biliary cholangitis (PBC). Third-party reporting said the results support seeking broader use…
• Acquisition-Related R&D ChargesImportance 28 · Surprise 42
  Gilead outlined a larger projected GAAP loss tied to sizeable acquired research and development charges. The digest does not quantify the charges, identify the acquired program, or provide a comparison with…
• Quarterly Dividend IncreaseImportance 25 · Surprise 32
  Gilead raised its quarterly dividend 3.8% to $0.82 per share, continuing an 11-year streak of annual increases. The reported cash payout ratio was 29.8%. The report said significant free cash flow growth and…

News · 2026-11-04

• Medicare Drug Price NegotiationImportance 64 · Surprise 42
  Jefferies estimated that the Inflation Reduction Act’s impact on Biktarvy revenue could be approximately $1 billion, versus Gilead’s initially guided $1.5 billion headwind. A separate report said a lower Medicare price…
• Oncology Pipeline ExpansionImportance 34 · Surprise 42
  Gilead and BioNTech are collaborating on a global Phase 3 trial of BioNTech’s pumitamig combined with a Gilead antibody-drug conjugate. The first-line regimen is being tested in metastatic triple-negative breast…
• T-Cell Engager Pipeline CollaborationImportance 34 · Surprise 42
  Vir Biotechnology reported a collaboration and license agreement with Gilead to discover and engineer three PRO-XTEN dual-masked T-cell engager development candidates. The agreement adds candidates to Gilead’s…
• Oncology Pipeline ProgressImportance 17 · Surprise 24
  Gilead and Kite announced 23 presentations, including seven oral presentations, for the December 12–15, 2026 American Society of Hematology meeting. Planned data include at least 18 months of follow-up on anito-cel’s…

News · 2026-11-03

• Competition and Market Share PressureImportance 40 · Surprise 42
  Dr. Reddy’s received tentative USFDA approval for a generic HIV-prevention injectable, which it plans to make available for $40 per year in 120 countries outside the United States. The product is being supplied through…
• HIV PrEP Licensing ExpansionImportance 31 · Surprise 42
  Gilead’s voluntary license enables Dr. Reddy’s to offer a generic HIV-prevention injectable in 120 countries outside the United States. The reported price is $40 per year, but the article does not disclose licensing…
• Product / Drug Pipeline ProgressImportance 17 · Surprise 24
  Gilead plans to present more than 50 studies at HIV Glasgow 2026, including late-breaking clinical data and real-world evidence. The presentations will cover HIV prevention, treatment, and cure research, with a focus…

News · 2026-11-02

• HIV PrEP Licensing ExpansionImportance 31 · Surprise 42
  The US FDA granted Dr. Reddy’s tentative approval for generic lenacapavir, which is being made available through a voluntary licensing agreement with Gilead under the PEPFAR program. The agreement is expected to enable…
• HIV Prevention Access ExpansionImportance 31 · Surprise 42
  Dr. Reddy’s received tentative U.S. FDA approval for generic lenacapavir, a twice-yearly injectable HIV-prevention drug, under the PEPFAR program and a voluntary licensing agreement with Gilead. The licensing…
• HIV Pipeline ExpansionImportance 17 · Surprise 24
  Gilead plans to present clinical data and real-world evidence from more than 50 studies at HIV Glasgow 2026, including late-breaking data and two oral presentations. The research will cover long-acting HIV treatment…

News · 2026-11-01

• Revenue Performance and MixImportance 30 · Surprise 40
  Trefis reported that faster sales growth in Gilead’s HIV drug segment was an early indicator cited by management as far back as February 2025. Regulatory filings showed revenue pickup throughout 2025. Revenue grew at a…

News · 2026-10-31

• Revenue Performance and MixImportance 27 · Surprise 32
  Gilead Sciences reported Q3 2026 sales of $8.3 billion, up 6.8% year over year and above market revenue expectations. Full-year revenue guidance was $31.15 billion at the midpoint, 1.3% above analysts’ estimates. Q3…
• Guidance and OutlookImportance 27 · Surprise 32
  Gilead's full-year 2026 revenue guidance was $31.15 billion at the midpoint. That midpoint was 1.3% above analysts' estimates. The digest provides no further detail on the guidance or the policy headwinds referenced in…

10-Q · 2026-10-30

• Acquisition and Pipeline ExpansionImportance 71 · Surprise 60
  During the second quarter of 2026, Gilead completed acquisitions of Arcellx, Tubulis and Ouro Medicines, adding oncology and inflammation assets and capabilities. The filing reports acquired in-process R&D expenses of…
• Acquisition and RestructuringImportance 65 · Surprise 60
  Acquired in-process research and development expenses totaled $11.3 billion for the nine months ended September 30, 2026, primarily reflecting $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion net for…
• Medicare Drug Price NegotiationImportance 48 · Surprise 48
  In October 2026, the Centers for Medicare and Medicaid Services completed setting the Maximum Fair Price for Biktarvy under Medicare. The negotiated price takes effect on January 1, 2028, and management states that it…
• Trodelvy Demand GrowthImportance 46 · Surprise 56
  Trodelvy product sales rose 42% to $506 million in the third quarter and 35% to $1.4 billion for the first nine months of 2026. Gilead attributed the growth in both periods primarily to higher demand. The filing also…
• Revenue Performance and MixImportance 43 · Surprise 32
  Total revenues increased 7% to $8.3 billion for the three months and $23.1 billion for the nine months ended September 30, 2026, compared with the same periods in 2025. Nine-month HIV product sales rose 14% to $17.0…
• Operating Expense TrendsImportance 40 · Surprise 48
  Selling, general and administrative expenses increased 21% to $1.6 billion for the three months ended September 30, 2026, and 26% to $5.0 billion for the nine months. Selling and marketing costs rose primarily because…
• Research and Development ExpenseImportance 35 · Surprise 40
  Research and development expenses increased 19% to $1.6 billion for the three months ended September 30, 2026, and increased 13% to $4.7 billion for the nine months. Nine-month personnel, infrastructure and support…
• Oncology Product ExpansionImportance 34 · Surprise 42
  Trodelvy received European Commission authorization in combination with Keytruda for eligible first-line metastatic triple-negative breast cancer patients whose tumors express PD-L1. The FDA also approved Trodelvy for…
• Regulatory Approval MilestonesImportance 34 · Surprise 42
  Gilead received FDA approval for Bixlenvo for adults with HIV who are virologically suppressed on a stable antiretroviral regimen, and FDA accelerated approval for Hepcludex for chronic hepatitis delta virus infection…
• HIV and PrEP Demand GrowthImportance 32 · Surprise 32
  HIV product sales increased 18% to $6.2 billion in the third quarter and 14% to $17.0 billion for the first nine months of 2026. Growth reflected higher demand and average realized prices, with favorable inventory…
• Liver Disease Sales GrowthImportance 26 · Surprise 32
  Liver Disease product sales increased 13% to $927 million in the third quarter and 8% to $2.6 billion for the first nine months of 2026. Higher demand for Livdelzi drove growth in both periods, with nine-month growth…
• Liquidity and Cash PositionImportance 25 · Surprise 24
  Cash and cash equivalents were $6.4 billion as of September 30, 2026. Net cash provided by operating activities increased to $11.152 billion for the nine months ended September 30, 2026, primarily due to lower income…
• In-Process R&D ImpairmentImportance 22 · Surprise 42
  Gilead recorded a $1.75 billion impairment charge during the nine months ended September 30, 2026, eliminating the remaining carrying value of its NSCLC in-process R&D intangible asset. The impairment followed the June…
• Cell Therapy CompetitionImportance 20 · Surprise 32
  Cell Therapy product sales declined 18% to $355 million in the third quarter and 15% to $1.2 billion in the first nine months of 2026. Gilead attributed the decreases to lower demand reflecting ongoing competitive…
• Gross Margin DriversImportance 18 · Surprise 32
  Product gross margin increased to 81.0% for the three months ended September 30, 2026, up 241 basis points from the prior-year period. For the nine months ended September 30, 2026, product gross margin was 79.9%, up…
• Veklury Sales DeclineImportance 10 · Surprise 64
  Veklury product sales fell 69% to $86 million in the third quarter of 2026 and 64% to $253 million for the first nine months. The filing attributes the declines to lower rates of COVID-19-related hospitalizations. The…
• Product Launch and TransitionImportance 10 · Surprise 60
  Gilead received FDA approval for Bixlenvo, a complete single-tablet HIV regimen for virologically suppressed adults, including patients switching from complex multi-tablet regimens. FDA accepted a supplemental NDA for…
• Income Tax Rate ChangesImportance 9 · Surprise 14
  The effective tax rate for the three months ended September 30, 2026, increased to 20.7% from 16.2% a year earlier, a 452-basis-point increase. The change primarily reflected a tax-authority settlement and…
• Quarterly Dividend DeclarationImportance 7 · Surprise 6
  In October 2026, Gilead’s board declared a quarterly dividend of $0.82 per common share. The dividend is payable December 30, 2026, to stockholders of record at the close of business on December 15, 2026. Future…

News · 2026-10-30

• HIV and PrEP Demand GrowthImportance 74 · Surprise 40
  Gilead’s HIV sales grew 18% year over year in the third quarter of 2026. Management attributed growth to Biktarvy, Descovy and Yeztugo, and said Biktarvy reached an all-time high in the U.S. Management expects HIV…
• Guidance and OutlookImportance 67 · Surprise 76
  CFO Andrew Dickinson raised 2026 product-sales guidance to $31.0 billion–$31.3 billion. The range includes base-business sales guidance of $30.7 billion–$31.0 billion, whose midpoint was raised by $900 million from…
• Medicare Biktarvy Price RegulationImportance 66 · Surprise 48
  Gilead expects Medicare pricing changes to create an approximately $1.5 billion revenue headwind in 2028 for Biktarvy, its key HIV drug. The company expects Biktarvy sales to decline in 2028 as a result. Management…
• Medicare Drug Price NegotiationImportance 66 · Surprise 48
  Gilead warned that Medicare pricing changes could reduce Biktarvy revenue by approximately $1.5 billion in 2028. The company expects Biktarvy sales to decline that year, while forecasting overall HIV revenue growth as…
• Revenue Performance and MixImportance 56 · Surprise 46
  Gilead’s third-quarter 2026 revenue increased 6.8% year over year to $8.3 billion, while product sales rose 13% to $8.29 billion. HIV, Trodelvy and Livdelzi supported growth, while Veklury sales fell 69% to $86…
• Net Income and EPS PerformanceImportance 46 · Surprise 30
  Gilead’s third-quarter 2026 net income declined 20.4% year over year to $2.43 billion, and diluted EPS fell 20.2% to $1.94. Adjusted earnings, by contrast, increased 3.2% to $2.55 per share and exceeded the Zacks…
• Veklury Sales DeclineImportance 45 · Surprise 64
  Veklury sales fell 69% year over year to $86 million in the third quarter of 2026. The report attributed the decline to lower COVID-19 hospitalizations, indicating weaker demand for the COVID-19 treatment. The reported…
• Canadian Reimbursement AccessImportance 37 · Surprise 42
  Gilead secured a pan-Canadian public reimbursement agreement for Livdelzi (seladelpar), which treats primary biliary cholangitis. The agreement with the pan Canadian Pharmaceutical Alliance supports future public…
• Trodelvy and Livdelzi DemandImportance 10 · Surprise 6
  Third-quarter reporting identified Trodelvy in metastatic breast cancer and Livdelzi in primary biliary cholangitis (PBC) among the products driving Gilead’s business growth. A separate report said Trodelvy and…

Earnings call · 2026-10-29

• Cell Therapy Manufacturing and ExpansionImportance 31 · Surprise 24
  Gilead is expanding its cell-therapy pipeline beyond multiple myeloma, including KITE-512, a GPC-3-targeted CAR T therapy for advanced hepatocellular carcinoma. The company has begun dosing an investigator-initiated in…
• Gamgertamig Clinical ProgressImportance 31 · Surprise 42
  Management said it expects to present additional gamgertamig data later this year, particularly in autoimmune cytopenia and immune thrombocytopenia. It characterized B-cell depletion as a broader opportunity across…
• Product Launch and TransitionImportance 31 · Surprise 42
  Gilead launched Bixlenvo in late August and said the launch was on track with expectations, while noting it was still early. Management reported strong awareness and said Bixlenvo was ahead of recent competitor…
• Capital Return ProgramImportance 30 · Surprise 6
  Gilead returned approximately $1.4 billion to shareholders in the third quarter of 2026. That amount included $370 million of share repurchases. Combined with dividends, the company returned approximately 40% of its…
• Operating Expense TrendsImportance 29 · Surprise 22
  Third-quarter non-GAAP R&D expense was $1.6 billion, up 19% year over year and 11% sequentially. Management attributed the R&D increase to higher compensation accruals related to year-to-date financial outperformance…
• Income Tax Rate ChangesImportance 28 · Surprise 42
  The third-quarter 2026 non-GAAP effective tax rate was 19%, in line with Gilead’s full-year expectation of approximately 20% excluding acquired IPR&D. The company’s reported full-year 2026 effective tax-rate guidance…
• Strategic InitiativesImportance 24 · Surprise 24
  Gilead described an eight-year strategy to diversify its portfolio across HIV treatment and PrEP, oncology, and inflammation. Management said the company is pursuing differentiated mechanisms in oncology, cell therapy,…
• Product / Drug Pipeline ProgressImportance 23 · Surprise 24
  Gilead is advancing oral and injectable HIV treatment options alongside Biktarvy and Bixlenvo, including a planned filing for once-weekly oral islatravir plus lenacapavir. Other programs include weekly oral…